ACM
GTHX

AlphaCrest Capital Management’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

AlphaCrest Capital Management’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-12,400
Closed -$298K – 1369
2021
Q1 		$298K Buy
+12,400
New +$288K 0.02% 1021

Other funds holding GTHX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AlphaCrest Capital Management's GTHX Position: Q2 2021 in Review

AlphaCrest Capital Management sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2021, closing a stake of 12,400 shares — an estimated $298K sold.

AlphaCrest Capital Management first reported a position in GTHX in Q1 2021 and held it in 1 quarter. The position peaked at $298K in Q1 2021. 114 funds tracked by Wall St. Rank hold GTHX as of Q2 2021.

  • AlphaCrest Capital Management reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • AlphaCrest Capital Management sold 12,400 G1 Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $298K.
  • AlphaCrest Capital Management first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • AlphaCrest Capital Management's G1 Therapeutics, Inc. Common Stock position peaked at $298K in Q1 2021.
  • 114 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2021.

Based on AlphaCrest Capital Management's 13F filing for Q2 2021, filed 12 Aug 2021.